Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06559618 · ClinicalTrials.gov registry record · Phase 1
Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
A Phase 1 study of Spinal Cord Injuries and Bacteriuria, sponsored by Barbara Wells Trautner.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06559618: Recruiting Phase 1 study of Spinal Cord Injuries and Bacteriuria, sponsored by Barbara Wells Trautner.
NCT06559618 is a Phase 1 study of Spinal Cord Injuries and Bacteriuria that is actively recruiting participants, run by Barbara Wells Trautner. The registered enrollment target is 30 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06559618, a Phase 1 study of Spinal Cord Injuries and Bacteriuria, is actively recruiting participants, sponsored by Barbara Wells Trautner.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1b study to assess the safety, tolerability, PK, and PD of investigational phage therapy (IP) in adults with SCI and bladder colonization (ASB). It is a single-center, randomized, double-blind, placebo-controlled study in adults with SCI with neurogenic bladders and bacteriuria who use indwelling catheters, or who require intermittent catheterization for bladder drainage.
Primary Outcome
Safety and tolerability analysis of Adverse Events. The urinary symptom questionnaires provided by MedStar Health, USQNB will be used as a daily study diary. Participant's charts for AEs while they are hospitalized, and during study visits on days 14, 21, and 35 if they have been discharged before Day 14. Blood samples will be collected for chemistry and hematology on days 1, 3, 7, 14, 21, and 35. Urine samples will be collected to detect and analyze markers of inflammation on Days 1, 2, 3, 5
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Phage Therapy
Study Locations (1)
Texas
- Michael E. DeBakey VA Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06559618 shows while recruiting
NCT06559618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (51% lower).
The record links to 4 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06559618 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06559618 about?
NCT06559618 is a clinical study titled "Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria". This is a Phase 1b study to assess the safety, tolerability, PK, and PD of investigational phage therapy (IP) in adults with SCI and bladder colonization (ASB). It is a single-center, randomized, double-blind, placebo-controlled study in adults with SCI with neurogenic bladders and bacteriuria who u...
What is the current status of trial NCT06559618?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-03. Estimated completion is 2026-12.
What conditions does trial NCT06559618 study?
This clinical trial studies the following conditions: Spinal Cord Injuries, Bacteriuria, Asymptomatic Bacteriuria, Escherichia Coli.
What interventions are being tested in trial NCT06559618?
The interventions under investigation include: Placebo (OTHER), Phage Therapy (DRUG).
Who is sponsoring clinical trial NCT06559618?
This trial is sponsored by Barbara Wells Trautner, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06559618 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06559618's enrollment target sits among peer trials
30 90th of 202 higher than 99 of 202 other Spinal Cord Injuries trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Cord Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NVG-291 in Spinal Cord Injury Subjects
RECRUITING · Phase 1
-
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
RECRUITING · Phase 1
-
Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
Temporary Inactivation of Strong Muscle Sensation to Improve Rehabilitation Interventions in SCI
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacological Agents for Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 1
-
Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy